Solrikitug Shows Strong Results in Esophagus Trial
Uniquity Bio's phase 2 ALAMERE trial reports positive topline results for solrikitug in adults with eosinophilic esophagitis.
Updated on Nov. 18, 2026 in Allergies

Uniquity Bio announced positive topline results from the ALAMERE phase 2 trial of solrikitug, a monoclonal antibody, in adults with eosinophilic esophagitis (EoE). The drug met its co-primary and key secondary endpoints versus placebo at week 24 across all doses tested and was well tolerated.
Why it matters
EoE is a chronic inflammatory condition of the esophagus driven by an allergic immune response, and its prevalence has risen roughly five-fold since 2009. Solrikitug targets thymic stromal lymphopoietin (TSLP), and the results support a planned pivotal phase 3 program that could provide clinical evidence for a regulatory filing.
The phase 2 trial's placebo-corrected histologic remission rates of 69%-76% at week 24 and dysphagia reductions of 8.8-12.6 points are topline figures from a randomized, double-blind, placebo-controlled study. Durability beyond week 24 and full data presentation remain pending as participants are tracked out to 52 weeks.
The players
Uniquity Bio
Uniquity Bio is a biopharmaceutical company developing solrikitug for allergic and inflammatory conditions, including eosinophilic esophagitis.
Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that in-licensed solrikitug to Uniquity Bio.
The details
ALAMERE was a randomized, double-blind, placebo-controlled trial evaluating solrikitug at three doses in adults with EoE, administered subcutaneously every four weeks. Uniquity Bio reported statistically significant results on co-primary and key secondary endpoints, with the drug well tolerated across all dose levels.
Timeline
Week 24: primary efficacy endpoints measured in the ALAMERE trial.
Week 52: planned follow-up for durability and safety.
First quarter of 2027: planned initiation of a phase 3 trial of solrikitug.
Early 2027: company expects to begin its pivotal phase 3 trial.
Big Picture
Solrikitug belongs to the TSLP-blocking antibody class, extending the approach used in allergic disease into eosinophilic esophagitis. Its phase 2 data add to the evidence that targeting this upstream cytokine can reduce esophageal inflammation.
For people living with EoE, the trial suggests a future treatment option that could reduce esophageal inflammation and dysphagia symptoms. The drug remains investigational, and no approved therapy or timeline for availability has been established.
The takeaway
Positive phase 2 data are an early step, and the pivotal phase 3 trial will determine whether solrikitug can become an approved option. Readers with EoE symptoms should discuss current management options with their clinician.
What happens next
Uniquity Bio plans to begin a pivotal phase 3 trial of solrikitug in the first quarter of 2027, with full ALAMERE results to be presented at a future medical congress.
Further reading
Explore more on Allergies to see how allergic immune responses drive conditions like eosinophilic esophagitis.
Source note: This article includes information reported by Pharmabiz.






